Roche/Pozen
Executive Summary
Pozen licenses serotonin (5HT2B) receptor antagonist MT-500 from Roche. Privately-held Pozen is pursuing a "license-back" strategy, in-licensing products from pharmaceutical companies to assume clinical development with the goal of licensing the products back to the innovator for marketing. The Chapel Hill, N.C. company expects to begin Phase II trials of MT-500 in 2000